Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Hewlett Packard Enterprise Co (HPE) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
Hewlett Packard Enterprise CoTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs Hewlett Packard Enterprise Co — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.61 (market cap $9.43B), while Hewlett Packard Enterprise Co trades at $56.19 (market cap $72.01B). The key difference: Hewlett Packard Enterprise Co is far larger — about 7.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Hewlett Packard Enterprise Co pays a 1.05% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

BIOHPE
Market Cap
$9.43B$72.01B
Sector
HealthTechnology
52-Week High
$356.25$56.14
52-Week Low
$241.71$20.01
Enterprise Value
$9.18B$87.96B
Dividend Yield
1.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.

BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.

Hewlett Packard Enterprise Co

HPE stock trades at $54.67, up 2.72% recently, with a bullish technical signal from moving averages but overbought RSI readings. The company has beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $0.925. Revenue grew to $34.30B in 2025, though net income fell sharply to $57M due to high investing cash outflows. Analysts maintain a consensus buy rating with a $69.81 price target, citing AI infrastructure demand.

The outlook is positive given AI-driven upgrades and institutional buying, but risks include volatile cash flows, elevated debt, and margin pressure. Investors should weigh strong analyst sentiment against execution risks in a competitive market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About Hewlett Packard Enterprise Co

Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.

Read more on HPE